Dopamine Metabolite Biomarkers and Testing for Disease Modification in Parkinson Disease

Peter A LeWitt^{1

2}

Affiliations

Comment

Peter A LeWitt. JAMA Neurol. 2020.

. 2020 Aug 1;77(8):1038-1039.

doi: 10.1001/jamaneurol.2020.1928.

Peter A LeWitt^{1

2}

¹ Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan.
² Henry Ford Hospital, Detroit, Michigan.

No abstract available

Comment in

Dopamine Metabolite Biomarkers and Testing for Disease Modification in Parkinson Disease-Reply.
Moussa C. Moussa C. JAMA Neurol. 2020 Aug 1;77(8):1039-1040. doi: 10.1001/jamaneurol.2020.1931. JAMA Neurol. 2020. PMID: 32597985 No abstract available.

Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial.
Pagan FL, Hebron ML, Wilmarth B, Torres-Yaghi Y, Lawler A, Mundel EE, Yusuf N, Starr NJ, Anjum M, Arellano J, Howard HH, Shi W, Mulki S, Kurd-Misto T, Matar S, Liu X, Ahn J, Moussa C. Pagan FL, et al. JAMA Neurol. 2020 Mar 1;77(3):309-317. doi: 10.1001/jamaneurol.2019.4200. JAMA Neurol. 2020. PMID: 31841599 Free PMC article. Clinical Trial.